期刊文献+

全脑放疗联合靶向药物与单独全脑放疗治疗非小细胞肺癌脑转移疗效及安全性的Meta分析 被引量:15

Comparison of the efficacy and safety between whole brain radiotherapy combined with targeted drugs and whole brain radiotherapy for non small cell lung cancer with brain metastasis:a Meta analysis
原文传递
导出
摘要 目的 采用Meta分析比较全脑放疗(WBRT)联合靶向药物与单用WBRT在非小细胞肺癌(NSCLC)脑转移瘤患者治疗中的疗效和安全性。方法 计算机检索Pubmed、Embase、中国知网、万方数据库中有关WBRT联合靶向药物治疗NSCLC脑转移的文献,检索时间均从建库至2016年5月。通过纽卡斯尔-渥太华量表(NOS)对文献进行质量评价,采用优势比(OR)及其95%可信区间合并效应量,采用Rev Man5.2软件进行数据分析。结果 最终纳入15篇研究文献,共计1 084例患者。结果显示:联合治疗组疾病控制率(OR:3.09,95%CI 2.11~4.54,P〈0.00001)、1年生存率(OR:2.55,95%CI 1.84~3.54,P〈0.00001)均高于单纯放疗组,差异具有明显统计学意义;安全性方面,联合治疗组皮疹发生率高于单纯放疗组(OR:9.10,95%CI 2.89~28.66,P=0.0002),但均属于Ⅰ~Ⅱ度不良反应,经对症处理后可缓解,其余不良反应如腹泻、恶心呕吐、乏力、骨髓抑制、呼吸困难两组比较均无统计学意义(P〉0.05)。结论WBRT联合靶向药物治疗NSCLC脑转移瘤明显优于单纯WBRT放疗,不良反应亦无明显增加。 Objective To compare the efficacy and safety between whole brain radiotherapy(WBRT) combined with targeted therapy and WBRT alone in the treatment of non-small cell lung cancer(NSCLC) with brain metastasis by Meta analysis. Methods A literature search was conducted among PubMed, Embase, Wanfang and the Chinese National Knowledge Infrastructure databases which related WBRT plus target therapy or WBRT alone in the treatment of NSCLC with brain metastases from inception to May, 2016. Studies quality was assessed by Newcastle-Ottawa Scale(NOS), odds ratios (OR) and 95% confidence intervals (Cls) as effect measures. The data analysis were performed using RevMan5.2. Results Fifteen eligible studies including 1 084 cases were included. Results showed that compared with WBRT alone, WBRT combined with targeted therapy showed higher disease control rate ( OR: 3.09, 95% CI 2.11-4. 54, P 〈 0.00001 ) and 1-year overall survival (OR: 2.55, 95% CI 1.84-3.54, P〈0.00001) , differences were statistical significance. In safety part, add targeted therapy were frequently had rash (OR: 9.10,95% CI 2.89-28.66, P = 0.0002), but all of them were 1-2 grade toxicity and could be tolerated. There were no significant differences in Diarrhea, nausea, vomiting, fatigue, bone marrow suppression and dyspnea(P〉0.05). Conclusion WBRT plus target therapy is superior to WBRT alone and well tolerated in the treatment of NSCLC with brain metastases. In addition, more high quality randomized controlled trials are needed.
出处 《中华肺部疾病杂志(电子版)》 CAS 2016年第4期366-371,共6页 Chinese Journal of Lung Diseases(Electronic Edition)
基金 国家自然科学基金资助项目(81271264)
关键词 非小细胞肺癌 脑转移 放疗 靶向治疗 META分析 Non-small cell lung cancer Brain metastasis Radiation therapy Targeted therapy Meta analysis
  • 相关文献

参考文献12

二级参考文献122

  • 1程刚.非小细胞肺癌的分子靶向药物治疗[J].中华肿瘤防治杂志,2007,14(5):387-390. 被引量:6
  • 2赵新汉,张晓智,常柏玲,等.肿瘤多学科综合治疗[M].西安:第四军医大学出版社,2007:626-627. 被引量:10
  • 3殷惠军,史大卓,张培彤,等.老年恶性肿瘤[M].北京:人民军医出版社,2010:427. 被引量:7
  • 4Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors[ J]. J Natl Cancer Inst ,2000 ;92 (3) :205-16. 被引量:1
  • 5Arrieta O,Saavedra-Perez D,Kuri R,et al. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer:a prospective analysis.BMC Cancer,2009,9:119. 被引量:1
  • 6Chen AM,Jahan TM,Jablons DM,et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer:clinical implications for the subsequent management of the brain.Cancer,2007,109:1668-1675. 被引量:1
  • 7Siker ML,Mehta ME Resection versus radiosurgery for patients with brain metastases.Future Oncol,2007,3:95-102. 被引量:1
  • 8Ma S,Xu Y,Deng Q,et al.Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.Lung Cancer,2009,65:198-203. 被引量:1
  • 9Kim JE,Lee DH,Cboi Y,et al.Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.Lung Cancer,2009,65:351-354. 被引量:1
  • 10Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States,National Cancer Institute of Canada.J Nail Cancer Inst,2000,92:205-216. 被引量:1

共引文献210

同被引文献120

引证文献15

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部